NCT07277777 2026-01-06
125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
Jinan Military General Hospital
Phase 2 Not yet recruiting
Clinical Trials
8 trialsNCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06063681 2025-06-08
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Stingray Therapeutics
Phase 1 Recruiting
NCT06889402 2025-03-21
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not yet recruiting
NCT06472713 2025-01-13
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Sun Yat-sen University
Phase 2 Recruiting
NCT03989336 2024-07-15
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Chinese PLA General Hospital
Phase 2 Completed
NCT05137886 2021-12-17
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04539444 2021-08-02
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown